|
|
Blood, 15 June 2004, Vol. 103, No. 12, pp. 4636-4643.
Prepublished online as a Blood First Edition Paper on March 2, 2004; DOI 10.1182/blood-2003-09-3068.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
Richard L. Piekarz,
Robert W. Robey,
Zhirong Zhan,
Ganesh Kayastha,
Anousheh Sayah,
Amina H. Abdeldaim,
Sonia Torrico, and
Susan E. Bates
From the Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.
Depsipeptide (FK228) is a novel histone deacetylase inhibitor currently in clinical trials and the first to demonstrate clinical activity in patients. Responses have been observed in patients with T-cell lymphomas, despite prior treatment with multiple chemotherapeutic agents. To better understand the effects of histone deacetylase inhibitors on T-cell lymphoma, the human T-cell lymphoma cell line HUT78 was tested for sensitivity and molecular response to depsipeptide. Treatment with depsipeptide, as well as other histone deacetylase inhibitors, caused induction of histone acetylation, induction of p21 expression, and substantial apoptosis without significant cell cycle arrest. Treatment with the caspase inhibitor z-VAD-fmk significantly inhibited depsipeptide-induced apoptosis, enabling detection of cell cycle arrest. Treatment with depsipeptide increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxicity. Cells selected for resistance to depsipeptide overexpressed the multidrug resistance pump, P-glycoprotein (Pgp). However, cells selected for resistance to depsipeptide in the presence of a Pgp inhibitor had a Pgp-independent mechanism of resistance. These studies confirm the activity of depsipeptide in a T-cell lymphoma model and suggest a general sensitivity of T-cell lymphoma to histone deacetylase inhibitors, an emerging new class of anticancer agents. (Blood. 2004;103:4636-4643)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. K.W. To, O. Polgar, L. M. Huff, K. Morisaki, and S. E. Bates
Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells
Mol. Cancer Res.,
January 1, 2008;
6(1):
151 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brest, M. Gustafsson, A.-K. Mossberg, L. Gustafsson, C. Duringer, A. Hamiche, and C. Svanborg
Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLET
Cancer Res.,
December 1, 2007;
67(23):
11327 - 11334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Oncologist,
October 1, 2007;
12(10):
1247 - 1252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Rodriguez, E Conde, A Gutierrez, R Arranz, A Leon, J Marin, M Bendandi, C Albo, M. Caballero, and On behalf of the Grupo Espanol de Linfomas/Traspla
The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience
Ann. Onc.,
April 1, 2007;
18(4):
652 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S. J. Mentzer, et al.
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Blood,
March 15, 2007;
109(6):
2571 - 2578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sanchez-Gonzalez, H. Yang, C. Bueso-Ramos, K. Hoshino, A. Quintas-Cardama, V. M. Richon, and G. Garcia-Manero
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Blood,
August 15, 2006;
108(4):
1174 - 1182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma.
Clin. Cancer Res.,
June 15, 2006;
12(12):
3762 - 3773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates
Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)
Clin. Cancer Res.,
March 1, 2006;
12(5):
1547 - 1555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Graham, C. Tucker, J. Creech, E. Favours, C. A. Billups, T. Liu, M. Fouladi, B. B. Freeman III, C. F. Stewart, and P. J. Houghton
Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo
Clin. Cancer Res.,
January 1, 2006;
12(1):
223 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood,
February 1, 2005;
105(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
